• Anahita Shaer, Negar Azarpira, Mahdokht H Aghdaie, and Elaheh Esfandiari.
• Anahita Shaer,Islamic Azad University, Fars Science & Research Branch, Fars, Iran. Transplant research Center, Shiraz University of Medical Science, Shiraz, Iran.
• Pak J Med Sci. 2014 Sep 1; 30 (5): 1022-6.

ObjectiveMesenchymal stromal cells (MSCs) are considered as an excellent source in regenerative medicine, but availability and ethical problems limited their routine use. Therefore, another available source with easy procedure and exempt from ethical debate is important. The purpose of this study is to isolate and characterize the MSCs from human placenta. The stromal cells were isolated from Placental Decidua Basalis (PDB-MSC), Umbilical cord Wharton's Jelly (WJ-MSC) and Amniotic Membrane (AM-MSC).MethodsFull term human placentas (n=4), from cesarean section delivery were collected. Small fragments from different parts were cultures as explants. The immunophenotyping, mesodermal differentiation, growth kinetics and stemness gene expression was studied.ResultsThe cultivated cells from three sources expressed CD44, CD105, and CD90. Gene expression of NANOG and OCT4 confirmed the undifferentiated state. The doubling-times for WJ-MSCs, PLC-MSCs and AM-MSCs, respectively, were 21±8h, 28±9h and 25±9h at passage three and 30±5h, 45±7h and 45±7h at passage tenth. The proliferative potential of WJ-MSCs tended to be higher than the other two sources.ConclusionThe fetal derives stromal cells; especially the early passages of WJ-MSCs are available supplies for large scale production of MSC for using in clinical studies or research projects.

4 keywords...

hide…